Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tolerability of IM vs Oral Meloxicam in Healthy Subjects
NCT02183090Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 1998
- Primary completion
- Dec 1998
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of meloxicam in osteoarthritis (OA) and rheumatoid arthritis (RA) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Plasma Drug Concentration-Time Curve from Time Zero to Infinity up to 96 hours, Maximum Drug Plasma Concentration up to 96 hours and 1 more. Started Nov 1998; status: completed.
02
Drugs
meloxicam
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02183090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183090.